| Cash Flow | 2026-03-31 | 2025-12-31 |
|---|---|---|
| Net loss | -2,174,836 | -3,738,821 |
| Depreciation and amortization | 12,306 | 63,257 |
| Stock based compensation | 128,440 | 516,180 |
| Amortization of license fees | 5,625 | 22,500 |
| Amortization of right-of-use assets, net of liabilities | 3,120 | 7,781 |
| Amortization of debt discount | 240,370 | 115,184 |
| Issuance of shares for services | 100,000 | NaN |
| Change in fair value of derivative liability | -148,766 | -7,737 |
| Loss on issuance of convertible note | -322,359 | -280,764 |
| Accounts receivable | 1,527 | 64,682 |
| Inventory | -11,694 | 69,052 |
| Prepaid expenses and other assets | 46,199 | -77,705 |
| Accounts payable | 111,941 | 496,242 |
| Accrued liabilities | -202,448 | 419,263 |
| Interest payable | 26,634 | 41,023 |
| Deferred revenue | 31,035 | -63,765 |
| Net cash used in operating activities | -1,288,960 | -1,919,720 |
| Purchases of intangible assets, including patents | 5,354 | NaN |
| Net cash used in investing activities | -5,354 | NaN |
| Proceeds from issuance of convertible notes payable | 250,000 | 988,472 |
| Proceeds from issuance of series d preferred stock | NaN | 192,338 |
| Proceeds from issuance of pre-delivery shares | NaN | 4,750 |
| Proceeds from issuance of series e preferred stock | 5,000,000 | NaN |
| Offering costs | 762,574 | 23,862 |
| Net cash provided by financing activities | 4,487,426 | 1,161,698 |
| Increase (decrease) in cash and cash equivalents | 3,193,112 | -758,022 |
| Cash and cash equivalents, beginning of year | 1,025,987 | 1,784,009 |
| Cash and cash equivalents, end of year | 4,219,099 | 1,025,987 |
20 20 Biolabs, Inc. (AIDX)
20 20 Biolabs, Inc. (AIDX)